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Abstrac t
 The  DEFB4  gene  copy  number s  were  investiga t e d  in  206  AD patient s  and
in  250  controls.  The  levels  of  the  human  defensin  - 2  (hBD2)  andβ  -α
defensins  (HNP  1-3)  in  the  sera  and  in  the  cerebrospinal  fluid  (CSF)  of
the  patiens  and  the  controls  were  dete rmine d  . 
Higher  copy  number s  of  the  DEFB4  gene  was  observed  in  AD patient s  as
compare d  with  the  controls.  The  levels  of  hBD- 2  and  HNP  1-3  were
significantly  elevated  in  the  sera  and  in  the  CSF  of  the  AD patient s  
These  data  sugges t  that  both  defensin  - 2  andβ  - defensins  have  poten tial  α
role  in  the  developme n t  of  AD.
1.  Introdu c t i o n
Initiating  event  in  AD  is  related  to  the  abnorm al  processing  of  beta-
amyloid  (A   ) ,  ultimately  leading  to  the  formation  of  A    plaques  in  the
brain  (Jack  et  al.,  2010) .  It  was   recently  postula ted   that  brain  infections
involving  bacte r ia  or  viruses  may  play  an  initiating  role  in  amyloid  plaque
formation  and  the  developme n t  of  AD (Hill  et  al.,  2014) ;  (Maheshw a r i  and
Eslick,  2015) ;  (Mawand a  and  Wallace,  2013) . Persis ten t  subclinical  CNS
infections  have  been  repor t ed  for  AD  patient s ,  caused  by  various
pathogens  such  as  Chlamydia  pneu m oniae ,  Helicobacter  pylori,  Herpes
simplex  virus I,  spiroche te s   or  even  fungi  (Shima  et  al.,  2010 ; Löwheim  et
al.,2015;  Miklossy  2011  ; Alonso  et  al,  2014)
It  is  presum e d ,  that  neuropa t hological  altera t ions  might  be  associa ted
with  abnorm al  expression  and  regula to ry  function  of  antimicrobial
peptides  (AMPs),  including  defensins  (Foste r  and  McVey  Neufeld,  2013) ;
(Williams  et  al.,  2012) .  Human  - defensins  have  been  sugges t ed  to  play  aβ
role  in  chronic  inflammation- associa ted  brain  injury,  a  risk  factor  for  AD.
In  this  respec t ,  the  litera tu r e  repor t s  (Williams  et  al.,  2012) ;  (Welling  et
al.,  2015)  lead  us  to  hypothesize  that  upregula tion  of   the  produc tion  of
defensins  might  trigger  the  aggrega t ion  of   amyloid  in  the  brain.  
Human  - defensins  include  human  neutrophil  peptide  1-4  (HNP1- 4)α
and  intestinal  human  defensins  (HD- 5  and  HD- 6),  produced  by  Paneth
cells.  Human  - defensins  make  up  another  family  of  antimicrobialβ
peptides  (Ganz,  2003);  (Pazgier  et  al.,  2006).  Besides  their  antibac t e r ia l
and  antiviral  effects ,  defensins  exert  numerous  immunological  effects
(Oppenheim  and  Yang,  2005);  (Yang  et  al.,  2002).  While  the  expression  of
human  defensin  beta- 1  (hBD1)  is  genera lly  consti tu t ive,  the  levels  of
human  defensin  beta- 2  (hBD2)  are  inducible  by  proinflam ma to ry
cytokines  and  bacte ria .
Defensin  genes  have  been  mapped  to  8p22- p23  (Linzmeier  and
Ganz,  2005) . A role  of  the  DEFB4  gene  in  dete rmining  human  -defensin-β
2  (hBD2)  as  potential  modifier  in  AD  has  not  been  hypothesized
previously.
We  therefore  conside red  it  of  interes t  to  investiga t e  the  relevance  of  the
copy  number  (CN)  polymorphism  of  the  DEFB4  genes  in  AD.  We
additionally  investiga t ed  the  levels  of   human  -defensin- 2  (hBD  2)  in  theβ
cereb rospinal  fluid  (CSF)  and  the  sera  of   the  patient s  with  AD.  The  study
was  supplem e n t e d  with  the  measu re m e n t  of  h uman  -defensin  (Humanα
Neut rophil  Peptide  1-3;  HNP1- 3)  in  the  circula tion  and  in  the  CSF.
2.  Materia l s  and  meth o d s
2.1  Patient s  and  controls
A total  of    206  AD patien ts  (69  men  and  137  women,  average  age
and  standa r d  deviation  (S.D.)  76.42  ±  4.21  years,  average  onset  at  65
years ) were  enrolled  in  the  study.  The  clinical  diagnosis  of  AD was  based
on  neurological  and  psychia t ric  examina tions ,  togethe r  with  the
assessm e n t  of  psychom et r ic  tests  to  confirm  cognitive  impairme n t .
Additionally,  a  brain  CT  scan  or  MRI  was  performe d  in  each  case.  All
par ticipan t s  fulfilled  criteria  of  NINCDS–ADRDA  (McKhann  et  al.,  1984) ;
(Dubois  et  al.,  2007) .  The  cognitive  evaluation  of  AD patient s  was  based
on  the  AD Assessme n t  Scale  – Cognitive  Subscale  (ADAS-Cog )  (Rosen  et
al.,  1984) ; (Pákáski  et  al.,  2012) , the  Mini- Mental  State  Exam  (MMSE)
(Folstein  et  al.,  1975) ; (Janka  et  al.,  1988) ,  and  the  Clock  Drawing  Test
(CDT)  (Kálmán  et  al.,  1995).  To  exclude  pseudode m e n t i a  caused  by
depression,  mood  was  scored  via  the  Beck  Depression  Invento ry  (Beck  et
al.,  1961) ,which  might  be  a  limitation  (Wagle  et  al.,  2000) ,  but  patient s
having  less  than  12  BDI   scores  have  only  been  included  to  the  study.
The  control  group  comprised  250  healthy  voluntee r s  (92  men  and  158
women,  average  age  ±  S.D.   72.69  ±  6.82  years)  with  normal  cognition.
(MMSE  score  higher  than  28)  
All cases  and  controls  were  of  Hunga ri an  ethnic  origin.  Informed  consen t
was  obtained  from  all  patien t s  or  responsible  guardian  in  case  of
incapacity  and  controls.  All  patient s  were  trea t ed  in  accorda nc e  with  the
Patient  Right’s  Protection  Act  of  our  insti tutions  and  according  to
interna t ional  guidelines .
The  local  Ethics  Commit tee  of  the  Hunga ri an  Investiga t ion  Review  Board
gave  prior  approval  to  the  study.  
2.2  Determina tion  of  DEFB4  Gene  Copy  Number  (CN)
Genomic  DNA  was  extrac te d  from  periphe r a l  blood  anticoagula t e d  with
EDTA  in  accordanc e  with  the  manufac tu r e r’s  instruc t ions  (High  Pure  PCR
Template  Prepar a t ion  Kit;  Roche  Diagnost ic  GmbH,  Mannheim,  Germany,
Cat.no:  1796828).  
A TaqMan  real- time  PCR  assay,  specifically  for  amplification  of  genomic
DEFB4,  was  performe d  as  described  previously  (Tiszlavicz  et  al.,  2012 ).
Briefly,  quanti t a t ive  DEFB4  amplifica tion  data  were  normalized  to  ABL
[FAM- lebeled  albumin  (Applied  Biosystems,  Cat.  No.  4331182)],  as  a
standa r d  referenc e  gene  conside red  to  be  presen t  only  in  2  copies  in  the
genom.  The  referenc e  gene  was  used  as  an  internal  standa r d  (Bentley  et
al.,  2010)  a dded  to  each  single  tube.  Quantifica tion  was  evaluate d  by  the
compara t ive  CT (Threshold  Cycle)  method  (Szilagyi  et  al.,  2006) .
2.3.  Determina tion  of  human  -defensin  2  (hBD2)  and  β HNP1- 3  
concen t r a t ions
ELISA  of  hBD2  (Alpha  Diagnos tic  San  Antonio,  TX, USA)  was  used  to  test
for  the  occur re nc e  of  the  human  -defensin  2  peptide  in  the  sera  and  inβ
CSF  of  the  controls  and  patient s ,  on  the  basis  of  manufac tu r e r’s
instruc t ions .  
The  HNP1- 3  concen t r a t ions  in  the  sera  and  CSF  were  determined  by  
ELISA  (Hycult- Biotech
HK324,  Uden,  The  Netherlands)  according  to  the  instruc t ions  of  the  
manufac tu r e r .
2.4.  Statistical  analysis
The  significance  of  the  differences  was  analyzed  by  the  Mann- Whitney
test.  The  GraphPad  prism  5  statis tical  progra m  was  used  for  all  statistical
calcula tions  (GraphPa d  Software  Inc.  San  Diego,  CA,  USA).  
3.  RESULTS
3.1.  Copy  number  (CN)  polymorphism  of  DEFB4
The  dete rmina t ion  of  CN  was  performe d  in  206  patient s  in  the  AD group
and  in  250  controls.  The  median  CN  in  the  controls  was  4,  the  75%
percen t ile  5,  and  the  25%  percen tile  was  3.  In  the  AD patient s  the  median
was  5,  with  a  75  %  percen tile  of  6,  and  with  a  25%  percen tile  of  4;
p<0.001  with  the  Mann- Whitney  test  (Fig.1.inse r t ) .
3.2.  Levels  of  hBD2  in  sera  and  in  cerebrospinal  fluids  (CSF)
The  levels  of  human  -defensin  2  were  dete rmine d  in  the  sera  of  52  ADβ
patient s  and    45  controls.  Significantly  higher  levels  of  hBD2  were
measu re d  in  AD patient s  than  in  the  controls  (Fig.1a.).  The  median  levels
were  265.5  pg/ml  in  AD vs.  169.4  pg/ml  respec tively  (p  <  0.01).
The  median  levels  of  -defensin  2  in  the  CSF  of  43  AD patient s  were  8.6β
pg/ml  vs  1.201  pg/ml  in  the  control  group  (n=40),  p  <  0.001  .Fig.1b.
3.3.  Levels  of  HNP1- 3  ( -defensin)α  in  sera  and  in  cereb ros pinal  fluids
(CSF)
The  median  serum  concen t r a t ions  of    -defensin  in  43  AD patien t s  wereα
147.3  ng/ml,  significantly  higher  than  that  in  40  controls:  122.3  ng/ml  ( p
<  0.05).  Fig.1c.
The  median  concent r a t ion  of  -defensin  α in  the  CSF  of  52  AD patient s  was
significantly  higher:  85.16  ng/ml  than  that  in  40  controls:  1.23  ng/ml,
p<0.001) .  Fig.1d.
4.  DISCUSSION
  It  has  been  postula te d ,  that  chronic  infections  might  be  initial  events  in
the  pathogen e s is  of  AD,  which  can  give  rise  to  persis ten t  inflamm ato ry
stimuli.  The  inflamma to ry  response  thereaf t e r  may  indirec t ly  lead  to  the
upregula t ion  of  amyloid   produc tion  β (Welling  et  al.,  2015) . Not  only  the
levels  of  the  inducible  hBD- 2  were  elevated  in  the  cerebros pinal  fluid  and
sera  of  AD patient s ,  but  also  those  of  HNP1- 3.  Our  data  are  in  accordanc e
with  recent  findings  (Watt  et  al.,  2015),  repor ting  that  the  levels  of
periphe r a l  -defensins  are  elevated  in  Alzheimer’s  disease .α  The  copy
number  polymorphism  of  the  DEFB4  gene  has  been  repor t ed  to  influence
the  produc tion  of  hBD2  (Linzmeier  and  Ganz,  2005) ; (Hollox  et  al.,  2008) ;
(Jansen  et  al.,  2009;   Tiszlavicz  et  al.,  2012) ;).  Accordingly,  in  our  study  a
significant  linear  correla tion  was  found  between  the  DEFB4  CN  and  the
serum  levels  (p  =  0.002;  r 2  =  0.196)  or  CSF  levels  (p  =  0.001;  r 2  =  0.222)
respect ively.  The  secre t ion  of  HNP  1-3  seems  to  be  independ e n t  of  the
copy  number  of  DEFA  gene  (Németh  et  al.,  2014) ,  and  we  therefore  did
not  investiga t e  it.  
The  presen t  study  suppor t s  the  view  of  the  potential  roleof  antimicrobial
peptides  such  as  human   and   - defensins  as  pathogen- targe t ing  agentsα β
in  brain  infections  with  respec t  to  the  pathology    of  AD.  Whethe r  the  AD
condition  is  the  conseque nc e  of  high  levels  of  defensins  which  induce
neurode g e n e r a t ion  and  A    formation,  or  the  elevated  levels  of  defensins
are  the  conseque n c e  of  AD is  curren tly  unknown.  Furthe r  investiga t ions
are  necessa ry  to  elucidat e  the  regula to ry  functions  of  defensins  in  the
pathomec h a ni s m  of  AD.
Lege n d  
Levels  of  hBD2  in  the  sera  (Fig1a)  and  in  the  cerebros pinal  fluids  (Fig1b);
levels  of  HNP1- 3  in  the  sera  (Fig  1c)  and  in  the  cereb ros pinal  fluids  
(Fig1d)  of  AD patient s  and  controls.  Horizontal  lines  repres e n t s  medians .  
Inser tion:  Individual  variation  in  copy  number s  of  DEFB4.
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